AIMC Topic: Immunotherapy

Clear Filters Showing 1 to 10 of 320 articles

Neoantigen-driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects.

Molecular biology reports
The development of neoantigen-based cancer vaccines has emerged as a groundbreaking approach in the field of personalized oncology. Neoantigens, originating from tumor-specific somatic mutations, possess considerable immunogenic potential and are abs...

Computational characterization and machine learning analysis of quantum optimized marine fungal metabolites targeting PD-L1 in cancer immunotherapy.

Journal of computer-aided molecular design
Cancer immune evasion is predominantly mediated through immune checkpoint pathways, such as the PD-1/PD-L1 axis. In this mechanism, PD-L1, which is often overexpressed on tumor cells, binds to PD-1 receptors on T cells, resulting in the inhibition of...

A Machine Learning Model Based on Clinical Factors to Predict the Efficacy of First-Line Immunochemotherapy for Patients With Advanced Gastric Cancer: Retrospective Study.

JMIR medical informatics
BACKGROUND: The development of immunotherapy has provided new hope for patients with advanced gastric cancer (AGC). However, due to the high heterogeneity of the disease, the efficacy of first-line immunochemotherapy varies among patients. There is s...

Interpretable multimodal radiopathomics model predicting pathological complete response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

Journal for immunotherapy of cancer
BACKGROUND: Accurate preoperative prediction of pathological complete response (pCR) following neoadjuvant chemoimmunotherapy (nCIT) could help individualize treatment for patients with esophageal squamous cell carcinoma (ESCC). This study aimed to d...

Decoding strategies for enhancing immunotherapy in head and neck squamous cell carcinoma.

International immunopharmacology
Immune checkpoint inhibitors have partially improved treatment outcomes for patients with head and neck squamous cell carcinoma (HNSCC), but the response rate remains low, with only a few patients benefiting. Mechanistically, HNSCC tumor cells often ...

Microbial Product Cocktails for Personalized Cancer Immunotherapy.

Nature communications
The human immune system has evolved to interact with various commensal and pathogenic bacteria in intricate and nuanced ways. While the diversity of bacteria presents fundamental challenges in understanding immune-microbe interactions, it also offers...

Drug resistance in cancer: molecular mechanisms and emerging treatment strategies.

Molecular biomedicine
Therapeutic resistance remains a defining challenge in oncology, limiting the durability of current therapies and contributing to disease relapse and poor patient outcomes. This review systematically integrates recent progress in understanding the mo...

Selectivity Approaches in Therapeutic Antibody Design.

Journal of medicinal chemistry
Protein therapeutics, particularly antibody-based therapies, have emerged as a cornerstone in modern disease treatment, offering key advantages over small molecules, including superior target specificity, longer half-life, and expanded target accessi...

A matrix stiffness gene signature identifies SLC20A1 as a novel mechano-immunological checkpoint enabling synergistic immunotherapy in pancreatic ductal adenocarcinoma.

Cancer immunology, immunotherapy : CII
Matrix stiffness is a defining feature of pancreatic ductal adenocarcinoma (PDAC) and drives malignant progression through mechanisms that remain poorly understood. Using an ensemble machine learning approach, we integrated multiomics data from 886 p...